NDAOPHTHALMICOINTMENT1 Generic Approved
Approved
Jul 1963
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Data completeness
5/8 — Partial
MAXITROL (neomycin sulfate, polymyxin b sulfate and dexamethasone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1963.
Drug data last refreshed 2m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXITROL is a triple-combination ophthalmic ointment containing neomycin sulfate, polymyxin B sulfate, and dexamethasone, approved since 1963. It functions as a corticosteroid hormone receptor agonist combined with broad-spectrum antibiotics to treat ocular infections and inflammation. The product is indicated for corticosteroid-responsive inflammatory conditions of the eye with concurrent bacterial infection risk.
$0.003BPart D
LOE ApproachingMinimal commercial activity with only 28 Medicare claims in 2023 indicates a niche, mature product with limited growth potential and likely a lean marketing team.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MAXITROL offers limited career growth in a declining, mature product with minimal commercial support and no active development pipeline. Roles are primarily focused on cost containment, regulatory compliance, and managing generic transition rather than innovation or market expansion.
Product Manager (Mature Portfolio)
Worked on MAXITROL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.